Myeloproliferative Neoplasms

Jacqueline S. Garcia, MD, discusses the role of ruxolitinib (Jakafi) in myelofibrosis.

John Mascarenhas, MD, discussed the effect of the data from MANIFEST on the treatment landscape and the future of adding active agents to ruxolitinib for treatment of myelofibrosis.

Andrew Ip, MD, discusses the use of targeted next-generation sequencing in detecting chromosomal structural abnormalities in patients with myeloid neoplasms.

Treatment with avapritinib led to clinically meaningful and statistically significant improvements in patient-reported symptoms and objective measures of mast cell burden in patients with non-advanced systemic mastocytosis.

The FDA has accepted a new drug application for momelotinib for the treatment of patients with myelofibrosis.

A combination regimen comprised of ruxolitinib and pomalidomide was found to be safe and feasible in a cohort of intermediate-2 and high-risk patients with primary or secondary myelofibrosis and anemia, according to data from the phase 1b/2 MPNSG-0212 trial.

The combination of azacitidine and quizartinib produced preliminary responses in patients with myelodysplastic syndrome and myelodysplastic syndrome/myeloproliferative neoplasms whose tumors harbored FLT3 or CBL mutations, according to data from a phase 1/2 trial (NCT04493138).

Ropeginterferon alfa-2b produced durable complete hematologic responses without phlebotomy and showcased a consistent safety profile in Japanese patients with polycythemia vera, according to findings from a phase 2 study (NCT04182100) presented during the 2022 EHA Congress.

Single-agent bomedemstat was found to improve symptom scores, bone marrow fibrosis, spleen volumes, and anemia in patients with advanced myelofibrosis, according to findings from the phase 1/2 IMG-7289-CTP-102 trial (NCT03136185) presented during the 2022 EHA Congress.

A combination comprised of selinexor (Xpovio) and ruxolitinib (Jakafi) induced rapid spleen responses at week 12 and showcased a manageable toxicity profile in patients with treatment-naïve myelofibrosis.

The panel has a conversation on risk stratification for myelofibrosis and how it individualizes their treatment approaches.

Dr Jamile Shammo explains the process of diagnosing myelofibrosis and highlights the importance of bone marrow biopsies.

Eltanexor has been granted a fast track designation from the FDA and an orphan medicinal product designation from the European Commission for use as a potential therapeutic option in patients with myelodysplastic syndromes.

A discussion on assessing symptom burden and quality of life for patients with essential thrombocythemia or polycythemia vera.

Ruben Mesa, MD, details an abstract presented at ASCO 2022 on an investigational agent filling an unmet need in polycythemia vera.

Raajit K. Rampal, MD, PhD, discusses the potential utilization of navtemadlin in relapsed/refractory acute myeloid leukemia and patients with blast phase myeloproliferative neoplasm in a phase 1b/2 trial.

An overview of the treatment options for patients with polycythemia vera.

Jamile Shammo, MD, FACP, FASCP, defines polycythemia vera and explains the process for diagnosis and risk stratification.

Dr Gustavo Rivero comments on novel treatment combinations and potential new biomarkers in patients with MDS.

Dr Ruben Mesa describes how he treats patients with essential thrombocythemia and the available treatment options.

Jeanne Palmer, MD, explains essential thrombocythemia and how it’s diagnosed.

Gustavo Rivero, MD, comments on the ongoing SELECT-MDS-1 trial and as well as reviewing the adverse events of the potential combination of tamibarotene with azacitidine in patients with higher-risk MDS.

Dr Gustavo Rivero reviews the treatment options for patients with newly diagnosed higher-risk MDS and discusses tamibarotene’s recent orphan drug designation.

Closing out their discussion on myelofibrosis, experts provide practical advice for identifying and managing patients in real-world practice.

Guadecitabine did not result in a statistically significant improvement in overall survival compared with physician’s choice of treatment in patients with relapsed/refractory myelodysplastic syndrome or chronic myelomonocytic leukemia, according to data from the phase 3 ASTRAL-3 trial.

Fedratinib was shown to be generally well tolerated in older patients with myelofibrosis who had received at least 3 months of prior ruxolitinib, according to findings from the phase 3b FREEDOM trial.

A new drug application seeking the approval of momelotinib for the treatment of patients with myelofibrosis has been submitted to the FDA.

Dr Gustavo Rivero talks about the significance of the RARA gene in patients with higher-risk MDS.

An overview of myelodysplastic syndrome (MDS) and the role of biomarker testing in patients with the disorder.

Single-agent navitoclax achieved a manageable safety profile compared with navitoclax plus ruxolitinib in patients with myelofibrosis. However, efficacy results, specifically at 24 weeks of treatment, favored the combination over navitoclax monotherapy.